12/11/2025
Synopsis of SUN IR Call – 2QFY26
Healthcare
• Healthcare recorded 1.7% YoY topline growth in 2QFY26, supported by volume expansion across the pharmaceutical, distribution, and retail segments. However, overall profitability was weighed down by a slowdown in Lina manufacturing and one-off incremental tax provisions from internal business model alignment.
• Pharma posted a 64.8% YoY increase in revenue, driven by 7.6% YoY volume growth, outpacing the broader industry growth of 7.3% YoY. New oral insulin products are expected to launch, helping regain lost market share in the this segment.
• Healthguard Pharmacy reported a 12.9% YoY revenue increase, primarily volume-driven and further supported by value growth as basket sizes continued to expand despite stable pricing.
• Lina Manufacturing recorded a 15% YoY revenue decline, mainly due to a reduction in government purchase orders for 2025.
Consumer
• Consumer recorded a 1.5% YoY revenue contraction in 2QFY26, primarily due to weaker performance in the export segment.
• The export business declined 9.2% YoY, driven by softer demand in high-value tea categories, following the adverse impact of U.S. tariff adjustments. However, revenue is expected to recover in the coming quarters, supported by steady demand from Western and Far Eastern markets during the festive season.
Agri
• Agri recorded a 23% YoY revenue increase in 2QFY26, mainly supported by the strong performance of the palm oil segment.
• Palm oil posted a 26% YoY growth in revenue, driven by an 11% YoY increase in production volumes and favorable pricing conditions.
• Dairy reported a 2.9% YoY increase in revenue, supported by a 3% YoY rise in milk sales volumes. However, margins came under pressure due to flat average milk prices compared to the previous year.
Copied.
CAL Research
WhatsApp Group Invite